Abstract is: Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML). The most common side effects are low levels of neutrophils (a type of white blood cell), diarrhea, nausea, anemia (low red blood cell counts), nose and throat infection and tiredness. Venetoclax attaches to a protein called Bcl-2. This protein is present in high amounts in CLL cancer cells, where it helps the cells survive for longer in the body and makes them resistant to cancer medicines. By attaching to Bcl-2 and blocking its actions, venetoclax causes the death of cancer cells and thereby slows down progression of the disease.
| P3780 | active ingredient in | Venclyxto | Q29006639 |
| Venclexta | Q47522280 | ||
| P366 | has use | medication | Q12140 |
| chemical probe | Q25326509 | ||
| P8026 | LiverTox likelihood score | LiverTox toxicity likelihood category E | Q83284667 |
| P2067 | mass | 867.318096 | |
| P2175 | medical condition treated | acute myeloid leukemia | Q264118 |
| mantle cell lymphoma | Q268713 | ||
| myelodysplastic syndrome | Q954625 | ||
| chronic lymphocytic leukemia | Q1088156 | ||
| non-Hodgkin lymphoma | Q1138590 | ||
| diffuse large B-cell lymphoma | Q2626074 | ||
| B-cell lymphoma | Q4833719 | ||
| P129 | physically interacts with | BCL2 apoptosis regulator | Q425201 |
| P2868 | subject has role | antineoplastic | Q2853144 |
| xenobiotic-transporting ATPase inhibitor | Q50348938 |
| Q113942412 | 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia |
| Q63338484 | A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma |
| Q113922684 | A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL |
| Q61969737 | A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) |
| Q113912377 | A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy |
| Q113945255 | A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia |
| Q113924830 | A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL |
| Q63013648 | A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations |
| Q86291992 | A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression |
| Q90693540 | A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia |
| Q63571492 | A Safety and Pharmacokinetics (PK) Study of Venetoclax in Participants With Non-Hodgkin's Lymphoma |
| Q113915289 | A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy |
| Q106637759 | A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC). |
| Q87930319 | A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer |
| Q106132115 | A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry ( |
| Q63404511 | A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy |
| Q113922768 | A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| Q63571415 | A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma |
| Q63571014 | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma |
| Q113927203 | A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) |
| Q63812156 | A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large |
| Q113890764 | A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML) |
| Q113912704 | A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants |
| Q113936101 | A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. |
| Q63592178 | A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy |
| Q63592345 | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies |
| Q62812512 | A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma |
| Q62809913 | A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
| Q63574079 | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy |
| Q63578291 | A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy |
| Q63229185 | A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy |
| Q63397909 | A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma |
| Q63811754 | A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
| Q86264679 | A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation |
| Q63011135 | A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies |
| Q63587235 | A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation |
| Q107169562 | A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML) |
| Q61975416 | A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199 |
| Q61975415 | A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199 |
| Q61864716 | A Study to Compare the Efficacy and Safety of Obinutuzumab + Venetoclax (GDC-0199) Versus Obinutuzumab + Chlorambucil in Participants With Chronic Lymphocytic Leukemia |
| Q87930804 | A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocy |
| Q62062441 | A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice |
| Q63572888 | A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell |
| Q107974251 | A Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter's Syndrome; |
| Q86291959 | A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progr |
| Q113920217 | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
| Q96143305 | APR-246 in Combination With Ibrutinib or Venetoclax-R in Subjects With TP53-Mutant R/R Non Hodgkin Lymphomas (NHL) |
| Q107974205 | Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| Q98605222 | Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML |
| Q97047744 | An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment |
| Q61975414 | An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma |
| Q96143293 | Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax |
| Q113910922 | Avo In R/R And Previously Untreated MCL |
| Q113922954 | Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure |
| Q63577998 | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia |
| Q113888559 | Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome |
| Q87930084 | BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Ther |
| Q113928502 | Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML |
| Q63587260 | Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma |
| Q61906943 | Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia |
| Q113944802 | CC-486 and Venetoclax for Acute Myeloid Leukemia |
| Q62035110 | CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL |
| Q113891284 | Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax |
| Q113898521 | Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia |
| Q113943273 | Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults |
| Q105788674 | Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old |
| Q113892623 | Copanlisib Plus Venetoclax in R/R DLBCL |
| Q107974257 | Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma |
| Q63581524 | Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. |
| Q63013620 | Cytarabine, Idarubicin, Liposome-encapsulated Daunorubicin-Cytarabine or Decitabine in Treating Older Patients With Acute Myeloid Leukemia |
| Q113918375 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia |
| Q113923802 | Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission |
| Q63595383 | Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer |
| Q113938041 | Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients With Relapsed or Refractory ALL or LL |
| Q104675340 | Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation |
| Q113887251 | Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy |
| Q86289178 | Ibrutinib + Venetoclax in Untreated WM |
| Q102152952 | Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) |
| Q63587725 | Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Older Patients With Untreated Chronic Lymphocytic Leukemia |
| Q62042586 | Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL |
| Q63575471 | Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia |
| Q63811638 | Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma |
| Q105786912 | Individualized Induction Therapy for Non-elderly AML Patients With Adverse Risk Features |
| Q63393186 | Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia |
| Q113928508 | Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma |
| Q63578656 | Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia |
| Q113928460 | Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML |
| Q106098557 | Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens |
| Q97045530 | Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia |
| Q113943227 | Microtransplantation Combined With Azacytidine to Improve the Efficacy of EAML |
| Q63595593 | Myeloma-Developing Regimens Using Genomics (MyDRUG) |
| Q113926053 | Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax |
| Q100789062 | Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma |
| Q87930639 | Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy |
| Q113919044 | Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 |
| Q63578777 | Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer |
| Q107213955 | Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) |
| Q113895146 | Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia |
| Q113894836 | Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia |
| Q105089354 | Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) |
| Q63573476 | Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy |
| Q113894457 | Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 |
| Q113944295 | Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax |
| Q113891571 | Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia |
| Q113896162 | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma |
| Q62031687 | Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A |
| Q113909679 | Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96 |
| Q99080925 | REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) |
| Q113945328 | Real World Outcomes Using Novel Agents for AML in the UK |
| Q113939917 | Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL |
| Q63397866 | Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL |
| Q62063038 | Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL |
| Q87930853 | Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
| Q113912619 | Safe Accelerated Venetoclax Escalation in CLL |
| Q95718158 | Safety And Efficacy Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Complete Remission and Overall Survival In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome |
| Q63591756 | Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL |
| Q99956142 | Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL |
| Q63405167 | Study Venetoclax Effectiveness and Real‐Life Treatment Management in Participants With Chronic Lymphocytic Leukemia |
| Q63813463 | Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML) |
| Q63578260 | Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia |
| Q63574652 | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL |
| Q113909955 | Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma |
| Q63812165 | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) |
| Q113914054 | Study of Magrolimab Combinations in Participants With Myeloid Malignancies |
| Q113893902 | Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations |
| Q96178839 | Study of Rituximab and Venetoclax in People With Newly Diagnosed Marginal Zone Lymphoma |
| Q113920209 | Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia |
| Q102152980 | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) |
| Q113929581 | Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms |
| Q86291719 | Study of Venetoclax in Combination With Azacytidine in AML Patients Selected Using Ex Vivo Drug Sensitivity Screening |
| Q63575894 | Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) |
| Q113921964 | Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy |
| Q106638170 | Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function |
| Q113939081 | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) |
| Q113921562 | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lympho |
| Q105088857 | Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma |
| Q63572007 | Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice |
| Q113921056 | Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Vene |
| Q113914053 | Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myelo |
| Q113926496 | Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML |
| Q86286945 | Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia |
| Q113912825 | Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients |
| Q113912539 | Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma |
| Q87076275 | Testing the Effects of Early Treatment With Venetoclax and Obinutuzumab Versus Delayed Treatment With Venetoclax and Obinutuzumab for Newly Diagnosed Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Do Not H |
| Q97047739 | The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) |
| Q63582055 | Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor |
| Q113938660 | Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax |
| Q89507802 | Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) |
| Q113915235 | Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and Venetoclax |
| Q63576986 | Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis |
| Q86291898 | Triple Combination of Pevonedistat and Venetoclax Plus Azacitidine in Adults With Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy |
| Q113914499 | Venetoclax + Azacitidine vs. Induction Chemotherapy in AML |
| Q113921804 | Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission |
| Q113924386 | Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML |
| Q63394044 | Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN |
| Q113941181 | Venetoclax Basket Trial for High Risk Hematologic Malignancies |
| Q113944198 | Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML |
| Q113923950 | Venetoclax Plus Inotuzumab for B-ALL |
| Q63229581 | Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
| Q63393687 | Venetoclax Registry |
| Q113895993 | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies |
| Q113913633 | Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia |
| Q63397091 | Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia |
| Q113938769 | Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia |
| Q113891960 | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia |
| Q113915984 | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms |
| Q63534969 | Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL |
| Q113888477 | Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) With Newly Diagnosed AML Eligible for Allo-SCT |
| Q62819144 | Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations |
| Q113890596 | Venetoclax and Irinotecan in Relapsed/Refractory SCLC |
| Q63573203 | Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia |
| Q63397941 | Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia |
| Q113929344 | Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia |
| Q104675224 | Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia |
| Q62041423 | Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma |
| Q62042204 | Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML |
| Q113923150 | Venetoclax in Patients With MDS or AML in Relapse After AHSCT |
| Q62815009 | Venetoclax in Treating Participants With Recurrent or Refractory Mature T-Cell Lymphoma |
| Q113942145 | Venetoclax to Augment Epigenetic Modification and Chemotherapy |
| Q113942009 | Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML |
| Q113898083 | Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome |
| Q63600621 | Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Participants With Patients Previously Untreated Acute Myeloid Leukemia |
| Q113917921 | Venetoclax, Dasatinib, Prednisone, and Rituximab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia |
| Q113928250 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid With Nivolumab (VIPOR-Nivo) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System |
| Q113912063 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma |
| Q63402393 | Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma |
| Q62823205 | Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma |
| Q113910000 | Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis |
| Q113909484 | Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) |
| Q99957008 | Venetoclax-Obinutuzumab +/- Ibrut in R/R CLL |
| Q64899051 | A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. |
| Q38640917 | ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development |
| Q48338418 | ABT-199 for chronic lymphocytic leukemia |
| Q87808204 | ABT-199 partners with azacitidine to contest myeloid malignancies |
| Q85244134 | ABT-199 shows effectiveness in CLL |
| Q38776895 | BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199. |
| Q38825797 | Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding |
| Q30395557 | Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199. |
| Q41009977 | Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. |
| Q36201548 | Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax |
| Q37725409 | Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells |
| Q88039589 | Correction: Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma |
| Q64096434 | Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia |
| Q37317447 | High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition |
| Q35974864 | Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199 |
| Q37376388 | Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells |
| Q36349985 | Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199) |
| Q54845659 | Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). |
| Q36426910 | MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. |
| Q35958056 | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia |
| Q64082232 | Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy? |
| Q42399858 | Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. |
| Q64259664 | Shedding Light on the Interaction of Human Anti-Apoptotic Bcl-2 Protein with Ligands through Biophysical and in Silico Studies |
| Q35920657 | Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1 |
| Q36990787 | Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia. |
| Q64056701 | Targeting Oxidative Stress With Auranofin or Prima-1 to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells |
| Q38827910 | Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. |
| Q60916539 | Targeting the Bcl-2 Family in B Cell Lymphoma |
| Q64111708 | The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome |
| Q94539872 | The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia |
| Q36735325 | Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions |
| Q89655653 | Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies |
| Q64107882 | Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose |
| Q425201 | BCL2 apoptosis regulator | physically interacts with | P129 |
| Category:Venetoclax | wikimedia | |
| Arabic (ar / Q13955) | فينيتوسلاكس | wikipedia |
| Venetoclax | wikipedia | |
| Venetoclax | wikipedia | |
| Venetoclax | wikipedia | |
| Vénétoclax | wikipedia | |
| ベネトクラクス | wikipedia | |
| or | ଭେନେଟୋକ୍ଲାକ୍ସ | wikipedia |
| Венетоклакс | wikipedia |
Search more.